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Abstract
Introduction: To estimate the incidence of intensive care unit (ICU)-acquired bloodstream infection (BSI) and its
independent effect on hospital mortality.
Methods: We retrospectively studied acquisition of BSI during admissions of >72 hours to adult ICUs from two
university-affiliated hospitals. We obtained demographics, illness severity and co-morbidity data from ICU databases
and microbiological diagnoses from departmental electronic records. We assessed survival at hospital discharge or
at 90 days if still hospitalized.
Results: We identified 6339 ICU admissions, 330 of which were complicated by BSI (5.2%). Median time to first
positive culture was 7 days (IQR 5-12). Overall mortality was 23.5%, 41.2% in patients with BSI and 22.5% in those
without. Patients who developed BSI had higher illness severity at ICU admission (median APACHE III score: 79 vs.
68, P < 0.001). After controlling for illness severity and baseline demographics by Cox proportional-hazard model,
BSI remained independently associated with risk of death (hazard ratio from diagnosis 2.89; 95% confidence
interval 2.41-3.46; P < 0.001). However, only 5% of the deaths in this model could be attributed to acquired-BSI,
equivalent to an absolute decrease in survival of 1% of the total population. When analyzed by microbiological
classification, Candida, Staphylococcus aureus and gram-negative bacilli infections were independently associated
with increased risk of death. In a sub-group analysis intravascular catheter associated BSI remained associated with
significant risk of death (hazard ratio 2.64; 95% confidence interval 1.44-4.83; P = 0.002).
Conclusions: ICU-acquired BSI is associated with greater in-hospital mortality, but complicates only 5% of ICU
admissions and its absolute effect on population mortality is limited. These findings have implications for the
design and interpretation of clinical trials.
Introduction
Nosocomial bloodstream infection (BSI) is a serious and
potentially preventable complication of hospitalization
and has been estimated to be the eighth leading cause
of death in the USA [1]. Critically ill patients are parti-
cularly vulnerable to hospital-acquired infections [2,3],
which are two to seven times more common in the ICU
[4-7] and can account for approximately half of all hos-
pital-acquired BSI [8].
ICU-acquired BSI has been estimated to complicate
between 1.2% and 6.7% of all ICU admissions [9-13],
4.4% to 6.8% of admissions of longer than 48 to 72
hours in duration [14-16] and have an incidence of
between 5 and 19 per 1,000 patient days [9,11,15].
These infections have been associated with increased
morbidity, mortality, and health care expenses [9,12-19].
As a consequence, considerable clinical and research
activity has been focused on attempts to improve patient
outcome by their prevention.
BSI is more common in patients who have surgery, are
immunocompromised, develop multiorgan dysfunction,
require mechanical ventilation or renal replacement ther-
apy, and have greater illness severity on ICU admission
[3,20,21]. Some critically ill patients may be genetically
predisposed to both developing BSI and dying in hospital
[22]. Thus BSI may be a marker of illness severity and
pre-morbid condition as well as a direct contributor to
adverse outcome. As a consequence, our ability to
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prevent BSI will be dependent on the baseline incidence
of BSI, the mortality rate of patients who develop it, and,
crucially, on its true independent influence on outcome
once correction has been made for other markers of ill-
ness severity.
Accordingly, we performed an observational study in a
large cohort of critically ill patients and sought to esti-
mate the incidence of BSI, the mortality rate of patients
who acquire BSI, and its independent influence of
mortality.
Materials and methods
Study population and data sources
We performed a retrospective observational analysis of
the incidence of BSI acquired during ICU admission at
two university-affiliated hospitals in Melbourne, Austra-
lia. Data were obtained from prospectively collected
electronic databases of ICU admissions and hospital
microbiology records of positive blood cultures. Stan-
dard protocols for the collection, analysis, and reporting
of blood cultures were employed. Complete data were
available for 11 years (Jan 1998 to Feb 2009) in one cen-
tre (Austin Hospital) and six years (Jan 2003 to Dec
2008) in the other (Monash Medical Centre). Local
ethics committee approval was obtained for re-analysis
of routinely collected data, waiving requirement for spe-
cific patient consent. Data were available on tip cultures
from intravascular devices in the Austin Hospital allow-
ing a sub-group analysis of proven catheter-associated
BSIs in this cohort of patients (72% of the total
population).
Definitions
We used Center for Disease Control (CDC) definitions
of ICU-acquired BSI (see Additional file 1) [23,24]; we
considered both primary and secondary BSIs in our ana-
lysis. Nosocomial BSI in the ICU was defined as blood
cultures taken in the presence of clinical evidence of
infection for a bacterium or fungus obtained more than
72 hours after admission to the ICU. Thus, we included
only those blood cultures taken after the third calendar
day of ICU stay as reported by previous investigators
[14,15,17,25].
Routine drawing of blood cultures was not ICU prac-
tice in the participating hospitals; we thus regarded all
positive blood cultures obtained in the ICU as indicative
of suspected infection.
In accord with CDC guidelines [24], we did not
include cultures of coagulase-negative staphylococci or
other common commensal skin organisms unless two
cultures separately isolated the same species of micro-
organism. The first positive culture after the third ICU
day was used to define the occurrence of ICU-acquired
BSI. To allow study of a population at risk, we
excluded all ICU admissions of less than 72 hours’
duration.
BSI was considered to be catheter-associated if there
was a positive tip culture from an intravascular device
removed in the two days before or after the positive
b l o o dc u l t u r ea n dt h em i c r o b iological isolates from tip
and blood were likely to represent the same infection
(same species or compatible mixed growth).
Aim
We sought to document the incidence of acquired BSI
in our ICU populations and to obtain an estimate of its
effect on subsequent survival. We hypothesized that
although BSI is likely to be associated with greater risk
of death in an individual its relative frequency in the
total ICU population might limit its impact on overall
mortality.
Data analysis
We merged ICU admission and microbiology result
databases and positive blood cultures paired with rele-
vant ICU admission data by date and unique patient
identifiers. Data were available on patient demographics,
admitting specialty, duration of ICU admission, Acute
Physiology and Chronic Health Evaluation III (APACHE
III) physiology score on admission, APACHE III chronic
health categories, need for mechanical ventilation or
renal replacement therapy during ICU stay, and death
during hospital admission.
To facilitate statistical analysis, APACHE III chronic
health categories were used to define patient groups that
might be at increased risk of BSI, namely: disseminated
malignancy (metastatic cancer, lymphoma, leukemia, or
myeloma), immunodeficiency (immunosuppression by ill-
ness or disease including HIV/AIDS), liver disease (hepa-
tic failure and cirrhosis), chronic kidney disease, chronic
pulmonary disease, and type 1 diabetes mellitus. Admis-
sion type was defined as surgical or non-surgical based
on hospital admitting unit. Survival was defined as survi-
val to hospital discharge or 90 days after ICU admission
if the patient was still in hospital.
We performed univariate comparisons using Graph-
Pad Prism version 5.0a for Mac OS (GraphPad Software,
San Diego, California, USA [26]) and multivariate analy-
sis and survival plots using R: A language and environ-
ment for statistical computing (R Foundation for
Statistical Computing, Vienna, Austria [27]) utilizing the
packages survival [28] and Design [29]. Categorical data
were reported as percentages, and compared using the
chi squared test with Yates’ correction. Continuous data
were reported as median with inter-quartile range (IQR)
and compared using the Mann-Whitney U test with
Gaussian approximation. For comparisons, statistical
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than 0.05.
Baseline risks for ICU-acquired BSI were examined in
a multivariate logistic regression analysis with backward
elimination of non-significant predictor variables. Sig-
nificance was assessed against the null model by chi
squared test of residual deviance, goodness-of-fit by
unweighted sum of squares test, and predictive ability
by calculation of the c-statistic. Independent predictors
of survival were modeled using a Cox proportional-
hazard analysis. As ICU-acquired BSI was not present
at baseline it was incorporated into the model as a
time-dependent co-variate [30], other factors were
either present at ICU admission (admission illness
severity, demographics, and comorbidities) or, in the
vast majority of cases, were initiated in the first 72
hours of ICU stay (mechanical ventilation and renal
replacement therapy) and were treated as time-indepen-
dent co-variates. We avoided the need to consider hos-
pital discharge as a competing endpoint by deeming all
patients discharged alive from hospital to have survived
to day 90 for the purposes of the survival analysis
rather than censoring them at time of discharge. The
proportional-hazard assumption was assessed by inspec-
tion of Schoenfeld residual plots. A Cox proportional-
hazard analysis was repeated to separately assess the
independent effect of the five most common microbio-
logical diagnoses, grouping similar organisms to pre-
serve statistical power. Similarly, in the cohort of
patients from the Austin hospital, we modeled the rela-
tive effect on survival of catheter-associated and non-
catheter-associated BSI.
Results
We studied 6,339 ICU admissions of more than 72
hours’ duration. ICU-acquired BSI complicated 5.2% of
these admissions (Table 1) and 9.5 new BSIs were
acquired in the ICU per 1,000 patient days at risk. Med-
ian time to first positive blood culture in those acquiring
BSI was seven days (IQR 5-12; Figure 1). Microbiologi-
cal classification of ICU-acquired BSI is shown in Table
2.
Univariate analysis
Univariate analysis is presented in Table 1. BSI was
associated with an 18.7% increase in crude hospital mor-
tality from 22.5% to 41.2%. However, as BSI was infre-
quent, crude mortality in the total population was
23.5%, only 1% greater than in patients who did not
acquire BSI (22.5%). This difference in mortality repre-
sents an unadjusted population attributable risk percen-
tage [31] of 4.3% - that is, before adjusting for
confounding variables, 4.3% of all deaths could be attrib-
uted to excess mortality after acquired-BSI.
During each full year of the study, rates of BSI varied
from 4.4% to 8.1%, overall mortality from 21.1% to
26.5% and crude mortality in patients with ICU acquired
BSI from 25% to 66%. However, there were no trends
toward a systematic alteration in these frequencies over
time (Figure 2).
Patients who developed acquired-BSI had greater ICU
length of stay than those who did not (median 15 days
vs. 5 days; P < 0.001). Patients acquiring BSI were also
significantly sicker at ICU admission and had more co-
morbidities (Table 1). Overall, 49 patients who devel-
oped BSI in the ICU were alive and in hospital 90 days
after ICU admission and were treated as survivors in
our analysis. Of these, only three subsequently died late
during their hospital stay, a rate similar to the overall
population.
Prediction of BSI
We examined risks for ICU-acquired BSI by developing
a logistic-regression model for its prediction (Table 3).
In this model, only higher APACHE III scores, the need
for renal replacement therapy, liver disease, and surgical
admission were risk factors for acquisition of BSI,
whereas older age lessened the odds of a diagnosis of
BSI. The model was significantly better than a null
model (P << 0.001); however, its predictive ability was
poor with a c-statistic of 0.63, implying that factors
beyond the baseline predictors examined had a large
influence on the development of BSI in the ICU.
Survival analysis
Controlling for baseline difference in a Cox proportional
hazard model, we confirmed that BSI was associated
with increased risk of death, with a hazard ratio for
death from the time of acquisition of BSI of 2.89 (Table
4). Acquired BSI infection was modeled as a time-
dependent covariate and the effect on actual survival in
the model was thus dependent on the time of acquisi-
tion of BSI (Figure 3). This model is dependent on the
validity of the proportional hazard assumption for
acquired BSI and inspection of residual plots confirmed
this was reasonable over the timescale in question (Fig-
ure 4). Accordingly for an individual, BSI occurring at
day seven (median time of acquisition) was associated
with an approximate 20% absolute increase in hospital
mortality compared with absence of BSI, when all other
baseline hazards were held at population means.
In Figure 5, we modeled the survival effect of all BSI,
occurring at the rate and times of acquisition observed
in the whole population, comparing against a group not
acquiring BSI, with all other baseline hazards held at
population means. In this model, the population attribu-
table risk of death at or before day 90 was 4.95% and
excess mortality in the entire study population,
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and independent of the other baseline hazards, was 1%.
Effect of microbiological diagnosis
We separately repeated our survival analysis to model
the effect of the five most common classes of BSI on
outcome (Table 5). In this analysis enterococci and coa-
gulase-negative staphylococci infections were not signifi-
cantly associated with survival while Staphylococcus
aureus and Gram negative infections both approximately
doubled the risk of death and candidemia was associated
with an over four-fold risk of dying in hospital.
Catheter-associated BSI
We assessed the possibility of catheter associated blood-
stream infection (CABSI) in 167 of 330 cases of BSI, in
127 of these an intravascular device tip was sent for cul-
ture in the two days either before or after a positive
blood culture. In 34 cases (20.4% of BSI), a positive tip
culture with a compatible microorganism identified likely
CABSI. CABSI microbiological isolates and types of intra-
vascular devices involved are shown in Tables 6 and 7,
respectively. Univariate comparison between catheter-
associated and non-catheter-associated BSI demonstrated
a non-significant trend toward lower hospital mortality
with CABSI (32.4% vs. 44.4%; P = 0.25; Table 8); how-
ever, in a Cox proportional-hazard analysis of all Austin
Hospital patients, the hazard ratio for in-hospital death
before 90 days linked with CABSI was 2.64 (95% confi-
dence interval (CI) = 1.44-4.83; P = 0.002 vs. no BSI;
Table 1 Characteristics of patients admitted to ICU for 72 hours or longer with univariate comparisons
All Admissions No Acquired BSI Acquired BSI P
Number of Admissions 6,339 6,009 (94.8%) 330 (5.2%)
APACHE III (admission) 68 (52-88) 68 (52-87) 78.5 (61-97) < 0.001
Age 64.9 (50-75) 65.0 (46-75) 62.6 (49-73) 0.02
Male Sex 62.1% 61.9% 65.2% 0.26
Surgical Admission 55.5% 55.4% 57.6% 0.48
Mechanical Ventilation 69.2% 69.2% 70.3% 0.79
Renal Replacement Therapy 6.7% 6.2% 15.2% < 0.001
Immune Deficiency 7.2% 7.0% 10.6% 0.02
Malignancy 15.1% 14.8% 19.1% 0.04
Liver Disease 7.0% 6.7% 12.4% < 0.001
Chronic Kidney Disease 3.8% 3.7% 4.8% 0.36
Chronic Pulmonary Disease 6.5% 6.6% 5.8% 0.64
Insulin-Requiring Diabetes 2.8% 2.7% 3.9% 0.27
ICU LOS (days) 6 (4-10) 5 (4-9) 15 (10-25) < 0.001
Hospital Mortality 23.5% 22.5% 41.2% < 0.001
For continuous variables median and inter-quartile range are shown.
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; LOS, length of stay.
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Figure 1 Histogram of time of diagnosis of ICU-acquired BSI.
Due to uncertainty over the exact time at which blood cultures
were taken, some taken in the fourth calendar day in the ICU (first
column) might have in fact been taken between 48 and 72 hours
after ICU admission. At the most 29 patients may have been miss-
attributed. Conversely, use of a later cut-off might exclude a similar
number of genuine ICU-acquired BSI. Analysis was designed to err
on the side of maximal inclusion. BSI, bloodstream Infection.
Table 2 Microbiological isolates during 330 ICU
admissions complicated by acquired bloodstream
infection
Microbiological Isolate Percentage of Admissions with
BSI
Gram negative Bacilli 28.2%
Staphylococcus aureus 26.7%
Coagulase-negative
staphylococci
24.3%
Enterococci 17.0%
Candida species 15.5%
Others 6.7%
In 44 admissions more than one species was isolated
BSI, bloodstream infection.
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associated with non-CABSI (hazard ratio = 3.18; 95%
CI = 2.43-4.17; P < 0.001 vs. no BSI; P = 0.57 vs. cathe-
ter-associated BSI; Table 8).
Discussion
Statement of main findings
We studied 6,339 admissions of greater than 72 hours
in two university-affiliated ICUs. We found that ICU-
acquired BSI complicated approximately 1 in 20 of
these admissions and that increased illness-severity,
surgery, immunological compromise, liver disease,
mechanical ventilation, and renal replacement therapy
predicted its occurrence. We further found that BSI
was independently associated with a close to three-fold
increased risk of death from the time of positive blood
culture and that the proportional hazard assumption
was robust. This implies that although the proportional
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Figure 2 Year on year trend in incidence of BSI (Panel a),
mortality in patients with BSI (Panel b) and all ICU admissions
of longer than 72 hours (Panel c) showing no significant trend
in change in these variables over the study period. BSI,
bloodstream Infection.
Table 3 Logistic regression analysis of risk factors for
acquired bloodstream infection
Risk Factor Odds Ratio 95% CI P
APACHE III (factor/point) 1.01 1.01-1.02 < 0.001
Age (factor/year*) 0.99 0.98-1.00 < 0.001
Renal Replacement Therapy 2.16 1.54-2.99 0.002
Liver Disease 1.45 1.00-2.06 0.041
Surgical Admission 1.28 1.02-1.63 0.037
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream
infection; CI, confidence interval.
*Odds ratio of 0.99/year equates to a 0.9 times change in odds of BSI with a
10 year increase in age.
Table 4 Cox-proportional hazard analysis for hospital
survival
Risk Factor Hazard Ratio 95% CI P
APACHE III (factor/point) 1.02 1.02-1.02 < 0.001
Age (factor/year*) 1.01 1.01-1.01 < 0.001
Acquired BSI 2.89 2.41-3.46 < 0.001
Surgical Admission 0.78 0.71-0.87 < 0.001
Liver Disease 1.34 1.12-1.61 0.001
Malignancy 1.23 1.08-1.40 0.002
Mechanical Ventilation 1.13 1.00-1.26 0.041
Immune Deficiency 1.18 0.99-1.40 0.059
Chronic Kidney Disease 1.18 0.94-1.48 0.148
Chronic Pulmonary Disease 1.15 0.95-1.39 0.162
Insulin-Requiring Diabetes Mellitus 1.18 0.90-1.54 0.221
Renal Replacement Therapy 1.09 0.92-1.30 0.334
Male Sex 0.98 0.89-1.09 0.767
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream
infection; CI, confidence interval.
*Hazard ratio of 1.01/year equates to a 1.1 times hazard for death with a ten
year increase in age.
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occurs early in ICU admission, when the baseline
rate of death is high, the absolute effect on chance of
survival is greater than if it occurs later in the course
of critical illness. We note, however, that residual
cofounders are likely to exist outside of our statistical
analysis, a suspicion supported by the weak ability of
the logistic-regression model to predict the develop-
ment of ICU-acquired BSI based on the presence of
the baseline predictors available. This suggests that
our assessment of the impact of acquired-BSI on survi-
val should be regarded as an upper-estimate of any
effect.
We also found that the collective effect of BSI on sur-
vival was statistically related to infections with candida,
S. aureus, and Gram-negative bacilli, while infections
with coagulase-negative staphylococci and enterococci
were not significantly associated with increased risk of
death in our dataset. In the cohort of patients from the
Austin Hospital, BSI identified as likely catheter-asso-
ciated remained a significant hazard for non-survival,
and risk of death was not significantly lower than that
related to non-catheter-associated BSIs.
Together these findings imply, that, because of the low
incidence and the estimated independent contribution to
mortality, the totality of BSI accounted for, at most, an
additional 1% excess mortality in the entire ICU popula-
tion. This adjusted effect of BSI is very close to the
unadjusted effect of BSI on survival. This may be
because, although patients with acquired BSI were sicker
and had more co-morbidities, they had to survive a cer-
tain length of time in order to be able to be diagnosed
and categorized with BSI. In our model these competing
effects appear to offset each other leading to the similar-
ity of the adjusted and unadjusted survival.
Relation to previous findings
Our incidence of BSI is similar to that reported in other
observational studies [9,11-15]. This similarity suggests
that our findings may have external validity. Our mor-
tality findings are also in agreement with previous stu-
dies of mortality among patients with BSI [9,11-14,
16,19,32,33] with an increased risk of death of about
Figure 3 The independent effect of acquired BSI on hospital
mortality in a Cox-proportional model of survival after ICU
admission of 72 hours or longer. Plots show predicted survival in
the absence of acquired bloodstream Infection (BSI) and with BSI
occurring at the median time (day 7) and the lower and upper
quartiles for time of acquisition (days 5 and 12). All other covariates
fixed at population means. Dotted lines show 95% confidence limits.
Figure 4 Plot of scaled Schoenfeld residuals versus
transformed time (based on Kaplan-Meir estimate of survival
function) demonstrating acceptable linearity for the
proportional hazard for the covariate Acquired BSI. Beta(t) is the
exponential associated with the covariate, equivalent to the natural
logarithm of the hazard ratio. The solid black line is a smoothing-
spline fit to the plot, with the broken lines representing a ± 2-
standard-error band around the fit. Grey line represents a
completely proportional (time-invariant) hazard ratio of 2.89. BSI,
bloodstream Infection.
Figure 5 Survival in the Cox-proportional hazard model in the
absence of acquired BSI and in the whole population of ICU
admissions lasting 72 hours or longer. In this model, at the
observed incidence of acquired bloodstream Infection (BSI) in the
whole population, only a 1% increase in total hospital mortality can
be associated with BSI. All other covariates fixed at population
means. Dotted lines show 95% confidence limits.
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lesser impact of BSI on mortality [10,34-41] suggesting
that the impact of BSI may vary with the setting and
methodology.
Our finding the infection with coagulase-negative sta-
phylococci did not confer significant additional risk of
death is in accord with findings that catheter-related
BSIs are less strongly associated with risk of death
[16,42,43]; however, this was not borne out in our analy-
sis of BSI with evidence of catheter infection. This sug-
gests that the virulence of the microorganism rather
than the source of infection may be more important in
determining outcome.
Finding an association between illness severity and
incidence of BSI in the ICU is in keeping with previous
reports [9,11-14]. Similarly need for renal replacement
therapy in the ICU is a documented risk factor for BSI
[44]. The negative association between increasing age
and decreased risk of developing BSI has also been
observed previously [45]. Older age may be associated
with a less pronounced inflammatory response to infec-
tion [46], consequently, the likelihood of blood culture
sampling may be lower, reducing observed incidence of
BSI in older patients.
Significance of study findings
Our study expands current knowledge of the incidence
and independent impact of ICU-acquired BSI on
survival. First, it suggests that the likely typical incidence
of acquired BSI in our ICU population is approximately
5%. This observation is a helpful comparator for control
groups in interventional trials aimed at reducing BSI.
This finding also suggests that conclusions from studies
where the “control” incidence of acquired BSI is higher
than this may not be directly transferable to all ICUs.
S e c o n d ,i tc o n f i r m st h a ts o m eI C U - a c q u i r e dB S Il i k e l y
contributes independently to an increased risk of death
and that prevention of these infections (predominantly
S. aureus,G r a mn e g a t i v ea n dCandida) is an important
therapeutic goal. Third, it suggests that catheter-asso-
ciated BSIs are clinically significant and their prevention
is also of importance. Finally, it identifies several impor-
tant factors that are associated with increased risk of
developing BSI. However, our study also indicates that
our ability to predict its development using baseline
characteristics and major interventions (surgery, renal
replacement therapy, and mechanical ventilation)
remains limited. Thus, from the data routinely available
early on in ICU admission, identification of a sub-group
of higher risk patients for BSI-preventive intervention
appears difficult. This observation is important, because
it suggests that more research is required to identify
patient characteristics, beyond those conventionally col-
lected near ICU admission, to allow better prediction of
risk of nosocomial infection. Better predictive models
might allow appropriate targeting of cumbersome or
Table 5 Cox-proportional hazard analysis for effect of microbiological diagnosis on hospital survival (only
microbiological co-variates are shown)
Microbiological Isolate Percentage of all admissions Unadjusted mortality Hazard Ratio 95% CI P
Candida species 0.8% 69% 4.60 3.23-6.57 < 0.001
Gram negative Bacilli 1.5% 38% 2.13 1.49-3.04 < 0.001
Staphylococcus aureus 1.5% 42% 2.07 1.48-2.90 < 0.001
Enterococci 0.9% 34% 1.49 0.93-2.39 0.10
Coagulase-negative staphylococci 1.3% 28% 1.23 0.78-1.94 0.36
None 94.8% 23% - - -
CI, confidence interval.
Table 6 Microbiological diagnosis in catheter-associated
bloodstream infection (BSI) and non-catheter-associated
BSI from 167 patients at Austin Hospital
Non-catheter-
associated BSI
Catheter-
associated BSI
Staphylococcus aureus 21.8% 17.7%
Coagulase negative
staphylococci
16.5% 23.5%
Enterococci 13.5% 11.8%
Gram negative Bacilli 24.8% 44.1%
Candida species 18.8% 5.8%
No significant difference in distribution of microbiological isolates between
groups, chi-squared test: P = 0.14.
Table 7 Intravascular devices associated with proven
ICU-acquired, catheter-associated bloodstream infection
during ICU admissions at Austin Hospital
Intravascular Device n (%)
Central venous catheter 16 (46%)
Dialysis catheter (non-tunnelled) 7 (20%)
Pulmonary artery catheter 6 (17%)
Peripherally inserted central catheter 2 (6%)
Arterial catheter 2 (6%)
Tunnelled central venous catheter 1 (3%)
Temporary pacing wire 1 (3%)
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of clinical studies examining such interventions.
The finding that BSI was independently associated
with a three-fold increased risk of death from the time
of positive blood culture implies that although the pro-
portional effect of BSI on mortality is constant over
time, if BSI occurs early in ICU admission, when the
b a s e l i n er a t eo fd e a t hi sh i g h ,t h ea b s o l u t ee f f e c to n
chance of survival is greater than if it occurs later in the
course of critical illness. We note, however, that residual
cofounders are likely to exist outside of our statistical
analysis, a suspicion supported by the weak ability of the
logistic-regression model to predict the development of
ICU-acquired BSI based on the presence of the baseline
predictors available. This suggests that our assessment
of the impact of acquired-BSI on survival should be
regarded as an upper-estimate of any effect.
Finally, because of the relatively low incidence of ICU-
acquired BSI in our population, ICU-acquired BSI
would account for only 5% of deaths, that is 1% excess
mortality in the total population. This observation has
several implications for randomized controlled trials of
interventions aimed at decreasing mortality by prevent-
ing ICU-acquired BSI. For example, a putative untar-
geted intervention capable of preventing 50% of ICU-
acquired BSI would be expected to reduce the overall
mortality of ICU patients staying for longer than 72
hours by only 0.5%. Accordingly, even a very effective
intervention would have to be administered to 200
patients to save one life. This effect is impossible to test
in any feasibly sized randomized controlled trial (in
excess of 100,000 patients would be required for ade-
quate power). Interventions to prevent BSI could have a
greater impact on survival by impacting sub-clinical,
undiagnosed, or localized infection. However, the
strength of such effects would need to be quantified if
investigators wish to be assured that interventional stu-
dies were adequately sized. Our data do suggest that use
of formally diagnosed BSI as a surrogate or secondary
endpoint in untargeted interventional studies may not
be feasible.
Study strengths and weaknesses
This study has several strengths. We used a large sample
of patients. Data were collected by dedicated data collec-
tors and electronically stored and were thus not amen-
able to manipulation or bias. Similarly, microbiological
data were collected as part of patient care. We assessed
the independent contribution of BSI to patient outcome,
providing useful information for trial design and for the
assessment of the relevant interventional literature.
On the other hand, our study also has some weak-
nesses. Its findings may not be directly generalizable to
differing microbiological environments worldwide. How-
ever, its results are comparable with those in similar stu-
dies conducted in the USA and Europe suggesting a
degree of external validity. During the 11-year study
period changes in case-mix, clinical workload, and clini-
cal practice could have affected incidence and outcome
of ICU-acquired BSI. However, no trend was evident on
inspection of the yearly data (see Additional file 1). By
examining this time-span we were able to include data
from over 6,000 ICU admissions making this one of the
largest studies of BSI in intensive care.
We did not have detailed clinical information includ-
ing exact trigger for drawing blood cultures, antimicro-
bial therapy, response to treatment, and cause of death.
Nor could we determine whether individual episodes of
BSI represented true infections. However, we excluded
commensal skin organisms isolated in single blood cul-
ture bottles, making it more likely that our isolates
represented true BSI. The association of such BSI with
illness severity, invasive interventions, and mortality all
support this notion. Furthermore, although exclusion of
a small number of non-clinically significant infections
might increase the attributable-mortality of BSI, this
would also decrease the observed incidence of BSI and
would thus be unlikely to substantially alter our estimate
of the effect of BSI on overall survival.
Our analysis of catheter-associated BSI was confined
to only one study centre. We required a positive tip cul-
ture to confirm a likely catheter source. Thus, we may
have missed some catheter-related infection although
Table 8 Characteristics and hospital mortality in patients
with microbiological evidence of catheter-associated
bloodstream infection (BSI) versus positive blood
cultures with no contemporaneous proven catheter
infection (median and inter-quartile range for univariate
comparison, hazard ratio (HR) with 95% confidence
interval for Cox analysis)
Catheter-
associated BSI
Non catheter-
associated BSI
P
Number (% of BSI) 34 (20.4%) 133 (79.6%)
Univariate
comparison
APACHE III
(admission)
66 (50-91) 72 (54-93) 0.41
Age (years) 59 (39-67) 61 (45-73) 0.32
ICU LOS (days) 17.5 (13-27) 15 (9-23) 0.21
Hospital Mortality 32.4% 44.4% 0.25
Cox hazard
analysis
HR for death in
hospital
2.64 (1.44-4.83) 3.18 (2.43-4.17) 0.57
APACHE, Acute Physiology and Chronic Health Evaluation; LOS, length of stay.
Data from Austin Hospital patient cohort only. Cox proportional-hazard
analysis incorporated all covariates used in Table 4.
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(about 20%) was similar to that reported by some pre-
vious investigators [9,14]. Conversely, in a few patients,
the catheter might have been secondarily infected by
blood-borne infection. However, by identifying a group
of patients with likely catheter-associated infection, we
were able to demonstrate that increased risk of death
remained significant in patients where a catheter source
of infection was very likely.
We did not compare patients developing BSI with a
matched control population. However, such retrospective
matching of controls is always approximate and suscepti-
b l et ou n m e a s u r e de f f e c t s .I no u rs t u d y ,w i t h o u td a y -
to-day clinical data on patients, we were limited to
adjusting for baseline factors and major interventions
(such as mechanical ventilation) usually commenced early
in ICU admission. We also did not assess the effect of
BSI on duration of ICU stay. However, the direction of
causality is very difficult to determine, because greater
length of exposure to risk will tend to increase the inci-
dence of BSI, while, at the same time, occurrence of BSI
will tend to delay ICU discharge. Given the inability to
assess direction of causality, we did not attempt to incor-
porate ICU length of stay into our statistical models. We
note that infections with coagulase-negative staphylo-
cocci, which would be expected to be more common
with greater length and complexity of ICU stay, were not
significantly associated with risk of death. This suggests
that the associations seen with mortality for other micro-
organisms are likely to be causative. However, because of
concerns about unmeasured confounders, our estimate of
attributable-mortality from ICU-acquired BSI should be
regarded as an upper estimate of any effect. Significantly,
however, even using this high estimate of attributable-
mortality, BSI had little impact on the overall survival of
the total population, contributing to, at most, an absolute
1% increase in hospital mortality.
Conclusions
In a study of over 6,000 ICU admissions lasting longer
than 72 hours, ICU-acquired BSI was associated with a
doubling in risk of death in hospital to approximately
40%. This correlation remained even after adjustment
for baseline illness severity, demographics, and co-mor-
bidities in a Cox proportional hazard model and was
almost entirely attributable to BSI with significant
pathogens. However, ICU-acquired BSI was uncommon
thus, although of great clinical impact to those indivi-
duals affected by it, its attributable excess mortality
could be, at most, 1% of the total population. This effect
implies that a) the survival benefit of untargeted inter-
ventions aimed at reducing the rate of proven ICU-
acquired BSI would be undetectable in any practically
sized controlled trial; b) claims of improved survival
from interventions aimed at reducing acquisition of BSI
in the ICU should be treated with caution.
Key messages
￿ Acquired BSI is independently associated with sig-
nificantly increased risk of death in critically ill
patients.
￿ This association persists for catheter-associated
BSI.
￿ These infections are relatively uncommon so that,
despite significance to individuals, their contribution
to overall mortality in an unselected population of
ICU patients is small.
Additional material
Additional file 1: Box 1. CDC/NHSN surveillance definition of health
care-associated infection. LCBI, Laboratory-confirmed primary
bloodstream infection [24].
Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; BSI: bloodstream
Infection; CABSI: catheter-associated bloodstream infection; CI: confidence
interval; IQR: inter-quartile range.
Acknowledgements
The authors would like to acknowledge the contribution of the laboratory
staff of the Departments of Microbiology Austin Health and Monash Medical
Centre.
Funding: Austin ICU Research Fund.
Author details
1Department of Intensive Care, Austin Hospital, 145 Studley Road,
Heidelberg, Victoria 3084, Australia.
2Department of Infectious Diseases,
Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia.
3Department of Intensive Care, Monash Medical Centre, 246 Clayton Road,
Clayton, Victoria 3168. Australia.
4Department of Microbiology, Monash
Medical Centre, 246 Clayton Road, Clayton, Victoria 3168. Australia.
5Department of Microbiology, Austin Hospital, 145 Studley Road, Heidelberg,
Victoria 3084, Australia.
6Australian and New Zealand Intensive Care Research
Centre, School of Public Health and Preventive Medicine, Monash University,
5 Commercial Rd, Prahran, Melbourne, Victoria 3181, Australia.
Authors’ contributions
JRP, JEE, EVL and RB conceived the study and devised the data analysis plan.
JRP and JEE performed background literature review. GCT, TMC, TMK, GKH,
PDRJ and BCM collected the primary datasets. NS collected additional data
on catheter-associated infection. JRP, JEE, EVL, NS and GCT performed data
analysis. JRP performed statistical analysis and wrote the manuscript. All
authors then reviewed the draft and had input to revision of the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 November 2010 Revised: 25 February 2011
Accepted: 21 March 2011 Published: 21 March 2011
References
1. Wenzel RP, Edmond MB: The impact of hospital-acquired bloodstream
infections. Emerg Infect Dis 2001, 7:174-177.
Prowle et al. Critical Care 2011, 15:R100
http://ccforum.com/content/15/2/R100
Page 9 of 112. Barsanti MC, Woeltje KF: Infection prevention in the intensive care unit.
Infect Dis Clin North Am 2009, 23:703-725.
3. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL: Severe
bloodstream infections: a population-based assessment. Crit Care Med
2004, 32:992-997.
4. Daschner F: Nosocomial infections in intensive care units. Intensive Care
Med 1985, 11:284-287.
5. Donowitz LG, Wenzel RP, Hoyt JW: High risk of hospital-acquired infection
in the ICU patient. Crit Care Med 1982, 10:355-357.
6. Weinstein RA: Epidemiology and control of nosocomial infections in
adult intensive care units. Am J Med 1991, 91:179S-184S.
7. Wenzel RP, Thompson RL, Landry SM, Russell BS, Miller PJ, Ponce de
Leon S, Miller GB: Hospital-acquired infections in intensive care unit
patients: an overview with emphasis on epidemics. Infect Control 1983,
4:371-375.
8. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB:
Nosocomial bloodstream infections in US hospitals: analysis of 24,179
cases from a prospective nationwide surveillance study. Clin Infect Dis
2004, 39:309-317.
9. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in
critically ill patients. Excess length of stay, extra costs, and attributable
mortality. JAMA 1994, 271:1598-1601.
10. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S: Attributable
morbidity and mortality of catheter-related septicemia in critically ill
patients: a matched, risk-adjusted, cohort study. Infect Control Hosp
Epidemiol 1999, 20:396-401.
11. Rello J, Ricart M, Mirelis B, Quintana E, Gurgui M, Net A, Prats G:
Nosocomial bacteremia in a medical-surgical intensive care unit:
epidemiologic characteristics and factors influencing mortality in 111
episodes. Intensive Care Med 1994, 20:94-98.
12. Vallés J, León C, Alvarez-Lerma F: Nosocomial bacteremia in critically ill
patients: a multicenter study evaluating epidemiology and prognosis.
Spanish Collaborative Group for Infections in Intensive Care Units of
Sociedad Espanola de Medicina Intensiva y Unidades Coronarias
(SEMIUC). Clin Infect Dis 1997, 24:387-395.
13. Brun-Buisson C, Doyon F, Carlet J: Bacteremia and severe sepsis in adults:
a multicenter prospective survey in ICUs and wards of 24 hospitals.
French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996,
154:617-624.
14. Garrouste-Orgeas M, Timsit JF, Tafflet M, Misset B, Zahar J-R, Soufir L,
Lazard T, Jamali S, Mourvillier B, Cohen Y, De Lassence A, Azoulay E,
Cheval C, Descorps-Declere A, Adrie C, Costa de Beauregard M-A, Carlet J,
OUTCOMEREA Study Group: Excess risk of death from intensive care unit-
acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis
2006, 42:1118-1126.
15. Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, Doig CJ:
Population-based assessment of intensive care unit-acquired
bloodstream infections in adults: Incidence, risk factors, and associated
mortality rate. Crit Care Med 2002, 30:2462-2467.
16. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group: Outcomes of
primary and catheter-related bacteremia. A cohort and case-control
study in critically ill patients. Am J Respir Crit Care Med 2001,
163:1584-1590.
17. Vincent J-L: Nosocomial infections in adult intensive-care units. Lancet
2003, 361:2068-2077.
18. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R,
Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II Group of Investigators:
International study of the prevalence and outcomes of infection in
intensive care units. JAMA 2009, 302:2323-2329.
19. Girou E, Stephan F, Novara A, Safar M, Fagon JY: Risk factors and outcome
of nosocomial infections: results of a matched case-control study of ICU
patients. Am J Respir Crit Care Med 1998, 157:1151-1158.
20. Magnason S, Kristinsson KG, Stefansson T, Erlendsdottir H, Jonsdottir K,
Kristjansson M, Jonmundsson E, Baldursdottir L, Sigvaldason H,
Gudmundsson S: Risk factors and outcome in ICU-acquired infections.
Acta Anaesthesiol Scand 2008, 52:1238-1245.
21. Pratikaki M, Platsouka E, Sotiropoulou C, Vassilakopoulos T, Paniara O,
Roussos C, Routsi C: Risk factors for and influence of bloodstream
infections on mortality: a 1-year prospective study in a Greek intensive-
care unit. Epidemiol Infect 2009, 137:727-735.
22. Henckaerts L, Nielsen KR, Steffensen R, Van Steen K, Mathieu C, Giulietti A,
Wouters PJ, Milants I, Vanhorebeek I, Langouche L, Vermeire S, Rutgeerts P,
Thiel S, Wilmer A, Hansen TK, Van den Berghe G: Polymorphisms in innate
immunity genes predispose to bacteremia and death in the medical
intensive care unit. Crit Care Med 2009, 37(192-201):192-201, e1-e3.
23. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for
nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
24. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of
health care-associated infection and criteria for specific types of
infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
25. Vallés J, Ferrer R: Bloodstream infection in the ICU. Infect Dis Clin North Am
2009, 23:557-569.
26. Graphpad Software. [http://www.graphpad.com].
27. R: A language and environment for statistical computing. [http://www.R-
project.org].
28. Survival: Survival analysis, including penalised likelihood. R package
version 2.35-7. [http://CRAN.R-project.org/package=survival].
29. Design: Design Package. R package version 2.3-0. [http://CRAN.R-project.
org/package=Design].
30. Cox Proportional-Hazards Regression for Survival Data. Appendix to An
R and S-PLUS Companion to Applied Regression. [http://cran.r-project.
org/doc/contrib/Fox-Companion/appendix-cox-regression.pdf].
31. Northridge ME: Public health methods–attributable risk as a link between
causality and public health action. Am J Public Health 1995, 85:1202-1204.
32. Higuera F, Rangel-Frausto MS, Rosenthal VD, Soto JM, Castañon J, Franco G,
Tabal-Galan N, Ruiz J, Duarte P, Graves N: Attributable cost and length of
stay for patients with central venous catheter-associated bloodstream
infection in Mexico City intensive care units: a prospective, matched
analysis. Infect Control Hosp Epidemiol 2007, 28:31-35.
33. Thompson DS: Estimates of the rate of acquisition of bacteraemia and
associated excess mortality in a general intensive care unit: a 10 year
study. J Hosp Infect 2008, 69:56-61.
34. Blot S, Vandewoude K, Colardyn F: Nosocomial bacteremia involving
Acinetobacter baumannii in critically ill patients: a matched cohort
study. Intensive Care Med 2003, 29:471-475.
35. Blot S, Vandewoude K, Hoste E, Colardyn F: Reappraisal of attributable
mortality in critically ill patients with nosocomial bacteraemia involving
Pseudomonas aeruginosa. J Hosp Infect 2003, 53:18-24.
36. Blot S, Vandewoude K, Hoste E, De Waele J, Kint K, Rosiers F, Vogelaers D,
Colardyn F: Absence of excess mortality in critically ill patients with
nosocomial Escherichia coli bacteremia. Infect Control Hosp Epidemiol
2003, 24:912-915.
37. Blot SI, Vandewoude KH, Colardyn FA: Evaluation of outcome in critically
ill patients with nosocomial enterobacter bacteremia: results of a
matched cohort study. Chest 2003, 123:1208-1213.
38. Blot SI, Vandewoude KH, Colardyn FA: Clinical impact of nosocomial
Klebsiella bacteremia in critically ill patients. Eur J Clin Microbiol Infect Dis
2002, 21:471-473.
39. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA: Effects of nosocomial
candidemia on outcomes of critically ill patients. Am J Med 2002,
113:480-485.
40. Digiovine B, Chenoweth C, Watts C, Higgins M: The attributable mortality
and costs of primary nosocomial bloodstream infections in the intensive
care unit. Am J Respir Crit Care Med 1999, 160:976-981.
41. Ylipalosaari P, Ala-Kokko TI, Laurila J, Ohtonen P, Syrjälä H: Intensive care
unit acquired infection has no impact on long-term survival or quality of
life: a prospective cohort study. Crit Care 2007, 11:R35.
42. Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ,
Decruyenaere J, Vogelaers D, Colardyn F, Vandewoude KH: Clinical and
economic outcomes in critically ill patients with nosocomial catheter-
related bloodstream infections. Clin Infect Dis 2005, 41:1591-1598.
43. Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE: Impact
of catheter-related bloodstream infections on the mortality of critically
ill patients: a meta-analysis. Crit Care Med 2009, 37:2283-2289.
44. Hoste EA, Blot SI, Lameire NH, Vanholder RC, De Bacquer D, Colardyn FA:
Effect of nosocomial bloodstream infection on the outcome of critically
ill patients with acute renal failure treated with renal replacement
therapy. J Am Soc Nephrol 2004, 15:454-462.
45. Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J,
Danneels C, Vandewoude K, Piette A, Vershraegen G, Van Den Noortgate N,
Prowle et al. Critical Care 2011, 15:R100
http://ccforum.com/content/15/2/R100
Page 10 of 11Peleman R, Vogelaers D: Epidemiology and outcome of nosocomial
bloodstream infection in elderly critically ill patients: a comparison
between middle-aged, old, and very old patients. Crit Care Med 2009,
37:1634-1641.
46. Gavazzi G, Krause KH: Ageing and infection. Lancet Infect Dis 2002,
2:659-666.
doi:10.1186/cc10114
Cite this article as: Prowle et al.: Acquired bloodstream infection in the
intensive care unit: incidence and attributable mortality. Critical Care
2011 15:R100.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Prowle et al. Critical Care 2011, 15:R100
http://ccforum.com/content/15/2/R100
Page 11 of 11